

Publications principales du directeur de thèse

Muller L, Fauvet F, Chassot C, Angileri F, **Coutant A**, Dégletagne C, Tonon L, Saintigny P, Puisieux A, Morel AP, Ouzounova M, Martinez P. EMT-driven plasticity prospectively increases cell-cell variability to promote therapeutic adaptation in breast cancer. *Cancer Cell International*, 2025.

Coutant A, Cockenpot V, Muller L, Dégletagne C, Pommier R, Tonon L, Ardin M, Michallet MC, Caux C, Laurent M, Morel AP, Saintigny P, Puisieux A, Ouzounova M*, Martinez P*. Spatial transcriptomics reveal pitfalls and opportunities for the detection of rare high-plasticity breast cancer subtypes. *Laboratory Investigation*, 2023.

Monteiro L*, **Da Silva L***, **Lipinski B***, Fauvet F, Vigneron A, Puisieux A, Martinez P. Assessing Cell Activities rather than Identities to Interpret Intra-Tumor Phenotypic Diversity and Its Dynamics. *iScience*, 2020.

Autres publications du directeur de thèse

J Bouaoud, P Bossi, M Elkabets, S Schmitz, LC van Kempen, P Martinez, S Jagadeeshan, I Breuskin, GJ Puppels, C Hoffmann, KD Hunter, C Simon, JP Machiels, V Grégoire, C Bertolus, RH Brakenhoff, S Koljenović, P Saintigny. Unmet Needs and Perspectives in Oral Cancer Prevention. *Cancers*, 2022.

E Truchard, C Bertolus, P Martinez, E Thomas, P Saintigny, JP Foy. Identification of a Gene-Expression-Based Surrogate of Genomic Instability during Oral Carcinogenesis. *Cancers* (Basel), 2022.

W Cross, M Mossner, S Nowinski, G Cresswell, A Banerjee, M Williams, L Gay, AM Baker, C Kimberley, H Davis, P Martinez, M Traki, V Walther, K Smith, G Caravagna, S Amarasingam, G Elia, A Berner, RC Choi, P Ramagiri, R Chauhan, N Matthews, J Murphy, A Antoniou, S Clark, JAC Aleong, E Domingo, I Spiteri, SAC McDonald, D Shibata, MM Lacle, LM Wang, M Moorghen, IPM Tomlinson, M Novelli, M Jansen, A Watson, NA Wright, J Bridgewater, M Rodriguez-Justo, H Kocher, SJ Leedham, A Sottoriva, TA Graham. Stabilising selection causes grossly altered but stable karyotypes in metastatic colorectal cancer. *bioRxiv* 2020.03.26.007138 doi:10.1101/2020.03.26.007138, 2020.

A Beddok, E Velleuer, F Sicre de Fontbrune, RH Brakenhoff, JH Dalle, C Dufour, S Faivre, C Genet, J Klijanienko, C Krieg, T Leblanc, P Martinez, R Peffault de Latour, A Rigolet, P Saintigny, D Stoppa Lyonnet, J Soulier, J Surralles, M Schramm, J Thariat. Strategies for early detection and detailed characterization of oral lesions and head and neck squamous cell carcinoma in Fanconi anemia patients. *Cancer Letters*, 2025.

CD Gatenbee, AM Baker, RO Schenck, M Strobl, J West, MP Neves, SY Hasan, E Lakatos, P Martinez, WCH Cross, M Jansen, M Rodriguez-Justo, CJ Whelan, A Sottoriva, S Leedham, M Robertson-Tessi, TA Graham, ARA Anderson. Immunosuppressive niche engineering at the onset of human colorectal cancer. *Nature Communications*, 2022.

RM Pommier, A Sanlaville, L Tonon, J Kielbassa, E Thomas, A Ferrari, AS Sertier, F Hollande, P Martinez, A Tissier, AP Morel, M Ouzounova, A Puisieux. Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution. *Nature communications*, 2020.

* Contributions égales

Publications de l'équipe

Defining precancer: a grand challenge for the cancer community. Faupel-Badger J, Kohaar I, Bahl M, Chan AT, Campbell JD, Ding L, De Marzo AM, Maitra A, Merrick DT, Hawk ET, Wistuba II, Ghobrial IM, Lippman SM, Lu KH, Lawler M, Kay NE, Tlsty TD, Rebbeck TR, Srivastava S; Precancer Think Tank Team. Nat Rev Cancer. 2024 Nov;24(11):792-809.

Virard F, Giraud S, Bonnet M, Magadoux L, Martin L, Pham TH, Skafi N, Deneuve S, Frem R, Villoutreix BO, Sleiman NH, Reboulet J, Merabet S, Chaptal V, Chaveroux C, Hussein N, Aznar N, Fenouil T, Treilleux I, Saintigny P, Ansieau S, Manié S, Lebecque S, Renno T, Coste I. Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death. Nat Commun. 2024 Aug 15;15(1):7037.

Dufresne A, Attignon V, Ferrari A, Tonon L, Boyault S, Tabone-Eglinger S, Cassier P, Trédan O, Corradini N, Vinceneux A, Swalduz A, Viari A, Chabaud S, Pérol D, Blay JY, Saintigny P. Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel. Cancer Med. 2024 Apr;13(7):e7115.

Le Meitour Y, Foy JP, Guinand M, Michon L, Karabajakian A, Fayette J, Saintigny P, Mahtouk K. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes. Oral Oncol. 2024 Feb;149:106680.

Bouvard V, Nethan ST, Singh D, Warnakulasuriya S, Mehrotra R, Chaturvedi AK, Chen TH, Ayo-Yusuf OA, Gupta PC, Kerr AR, Tilakaratne WM, Anantharaman D, Conway DI, Gillenwater A, Johnson NW, Kowalski LP, Leon ME, Mandrik O, Nagao T, Prasad VM, Ramadas K, Roitberg F, Saintigny P, Sankaranarayanan R, Santos-Silva AR, Sinha DN, Vatanasapt P, Zain RB, Lauby-Secretan B. IARC Perspective on Oral Cancer Prevention. N Engl J Med. 2022 Nov 24;387(21):1999-2005.

Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, Fekiri D, Robert M, Baffert KA, Hervé G, Quilhot P, Attignon V, Girod A, Chaine A, Benassarou M, Zrounba P, Caux C, Ghiringhelli F, Lantuejoul S, Crozes C, Brochériou I, Pérol M, Fayette J, Bertolus C, Saintigny P. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients. Eur J Cancer. 2022 Oct; 174:287-298.

Ortiz-Cuaran S, Swalduz A, Foy JP, Marteau S, Morel AP, Fauvet F, De Souza G, Michon L, Boussageon M, Gadot N, Godefroy M, Léon S, Tortereau A, Mourksi NE, Leonce C, Albaret MA, Dongre A, Vanbervliet B, Robert M, Tonon L, Pommier RM, Hofman V, Attignon V, Boyault S, Audouyoud C, Auclair J, Bouquet F, Wang Q, Ménétrier-Caux C, Pérol M, Caux C, Hofman P, Lantuejoul S, Puisieux A, Saintigny P. Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer. Eur J Cancer. 2022 Jul; 169:106-122.

Rousseau B, Bieche I, Pasmant E, Hamzaoui N, Leulliot N, Michon L, de Reynies A, Attignon V, Foote MB, Masliah-Planchon J, Svrcek M, Cohen R, Simmet V, Augereau P, Malka D, Hollebecque A, Pouessel D, Gomez-Roca C, Guimbaud R, Bruyas A, Guillet M, Grob JJ, Duluc M, Cousin S, de la

Fouchardiere C, Flechon A, Rolland F, Hirt S, Saada-Bouazid E, Bouche O, Andre T, Pannier D, El Hajbi F, Oudard S, Tournigand C, Soria JC, Champiat S, Gerber DG, Stephens D, Lamendola-Essel MF, Maron SB, Diplas BH, Argiles G, Krishnan AR, Tabone-Eglinger S, Ferrari A, Segal NH, Cercek A, Hoog-Labouret N, Legrand F, Simon C, Lamrani-Ghaoui A, Diaz LA, Saintigny P, Chevret S, Marabelle A. PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. *Cancer Discov.* 2022 Jun 2;12(6):1435-1448.

Bouaoud J, Foy JP, Tortereau A, Michon L, Lavergne V, Gadot N, Boyault S, Valantin J, De Souza G, Zrounba P, Bertolus C, Bendriss-Vermare N, Saintigny P. Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free survival. *Oncoimmunology.* 2021 Jun 27;10(1):1944554.

Karabajakian A, Bouaoud J, Michon L, Kamal M, Crozes C, Zrounba P, Auclair-Perossier J, Gadot N, Attignon V, Le Tourneau C, Benzerdjeb N, Fayette J, Saintigny P. Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. *Oral Oncol.* 2021 Aug;119:105368.

Gobbini E, Swalduz A, Levra MG, Ortiz-Cuaran S, Toffart AC, Pérol M, Moro-Sibilot D, Saintigny P. Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. *Cancers (Basel).* 2020 Oct 24;12(11):3112.

Albaret MA, Paré A, Malet L, De Souza G, Lavergne E, Goga D, De Pinieux G, Castellier C, Swalduz A, Robin V, Lavergne V, Mertani HC, Treilleux I, Vermot-Desroches C, Diaz JJ, Saintigny P. Combined proteomic and transcriptomic approaches reveal externalized keratin 8 as a potential therapeutic target involved in invasiveness of head and neck cancers. *Transl Oncol.* 2021 Jan;14(1):100878.

Mezquita L*, Swalduz A*, Jovelet C, Ortiz-Cuaran S, Howarth K, Planchard D, Avrillon V, Recondo G, Marteau S, Benitez JC, De Kievit F, Plagnol V, Lacroix L, Odier L, Rouleau E, Fournel P, Caramella C, Tissot C, Adam J, Woodhouse S, Nicotra C, Auclin E, Remon J, Morris C, Green E, Massard C, Pérol M, Friboulet L, Besse B, Saintigny P. Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. *JCO Precis Oncol.* 2020 Apr 2;4:PO.19.00281. *equal contribution

Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Lorient Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Aït Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, Besse B, Blay JY, Saintigny P, Planchard D. Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer. *Clin Cancer Res.* 2020 Dec 1;26(23):6242-6253.

Foy JP, Bertolus C, Boutolleau D, Agut H, Gessain A, Herceg Z, Saintigny P. Arguments to Support a Viral Origin of Oral Squamous Cell Carcinoma in Non-Smoker and Non-Drinker Patients. *Front Oncol.* 2020 May 21;10:822.